硫酸黏菌素联合头孢哌酮钠舒巴坦钠治疗多重耐药鲍曼不动杆菌的疗效
| 作者: |
1史丽英,
2史丽珠,
1马燕
1 太原市中心医院老年病科，太原 030009 2 丹东市中心医院CT科，辽宁 丹东 118002 |
| 通讯: |
史丽珠
Email: 396932421@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2022.03.010 |
摘要
目的：探讨硫酸黏菌素联合头孢哌酮钠舒巴坦钠治疗多重耐药鲍曼不动杆菌肺炎的疗效分析。方法：选择2019年3月至2021年7月太原市中心医院收治的76例多重耐药鲍曼不动杆菌肺炎患者为研究对象，按照随机数字表法分为对照组(n=37)与观察组(n=39)。对照组静脉滴注注射用头孢哌酮钠舒巴坦钠，3 g加入到0.9%氯化钠溶液100 mL中，每隔6 h静脉滴注1次；观察组静脉滴注注射用头孢哌酮钠舒巴坦钠联合注射用硫酸黏菌素，用法为硫酸黏菌素100万U/d，分2次静脉滴注。两组疗程均为14 d。观察两组患者的临床疗效，比较两组患者白细胞计数(white blood cell count，WBC)、血清C反应蛋白(C-reaction protein，CRP)、降钙素原(procalcitonin，PCT)水平以及不良反应。结果：观察组与对照组有效率差异有统计学意义(P<0.05)；观察组WBC、CRP和PCT水平显著低于对照组(P<0.05)。结论：针对多重耐药鲍曼不动杆菌肺炎患者，硫酸黏菌素联合头孢哌酮钠舒巴坦钠有效率、炎症指标优于单用头孢哌酮钠舒巴坦钠组，不良反应无明显增加。
关键词：
多重耐药鲍曼不动杆菌；硫酸黏菌素；头孢哌酮钠舒巴坦钠；白细胞计数；降钙素原
Efficacy of colistin sulfate and cefoperazone/sulbactam in the treatment of multidrug-resistant Acinetobacter baumannii
CorrespondingAuthor: SHI Lizhu Email: 396932421@qq.com
DOI: 10.3978/j.issn.2095-6959.2022.03.010
Abstract
Objective: To explore the efficacy of colistin sulfate and cefoperazone/sulbactam in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia. Methods: From March 2019 to July 2021, 76 patients with multidrug-resistant Acinetobacter baumannii pneumonia were divided into a control group and an observation group according to the method of random number table. The control group was treated with cefoperazone/sulbactam 3 g per 6 hours, the observation group was treated with cefoperazone/sulbactam (3 g) and colistin (1 million units) per day, the treatment course was 14 days. The clinical efficacy and inflammatory factors were observed, including the white blood cell count (WBC), serum C-reactive protein (CRP), and procalcitonin (PCT). Results: The difference of the effective rates between the 2 groups was statistically significant (P<0.05); the WBC, CRP and PCT levels of the observation group were significantly lower than those of the control group (P<0.05). Conclusion: For patients with multi-drug-resistant Acinetobacter baumannii pneumonia, clinical efficacy and inflammatory factors treated with colistin sulfate combined with cefoperazone/sodium are better than those treated with cefoperazone/sodium, without obvious increasing adverse reactions.
Keywords：
Acinetobacter baumannii; colistin sulfate; cefoperazone/sulbactam; white blood cell count; procalcitonin